B

Breast Cancer Research Centre - WA | Nedlands, Australia

Research site

(Unclaimed)

Location

91, Monash Avenuenue, Suite 407, Level 4, Nedlands, Western Australia, Australia

Site insights

Top conditions

Top treatments

Palbociclib

Nivolumab

Anastrozole

Sacituzumab

Trastuzumab

SBT6050

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

Active, not recruiting

HER2 Positive Solid Tumors

Drug: SBT6050

Drug: Cemiplimab

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting

HER2-Positive Primary Breast Cancer

Residual Invasive Breast Cancer

Drug: DS-8201a

Drug: T-DM1

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Palbociclib

Locations recently updated

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Enrolling

Locally Advanced or Unresectable Metastatic Breast Cancer

Stage IV Breast Cancer

Drug: Paclitaxel

Drug: Capecitabine